Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Novartis hopes of blockbuster status for Rasilez dashed - PMLiVE |
 |
 |
|
PMLiVE Novartis has abandoned a trial of its renin inhibitor Rasilez/Tekturna in high-risk patients with diabetes and renal impairment after seeing higher rates of adverse events in patients receiving the drug. The ALTITUDE study was intended to position ... Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in |
